Johnson & Johnson halts mid-stage trial of experimental eczema drug
Strong Bearish
-100.0
Johnson & Johnson said it discontinued a mid-stage study of its experimental drug to treat atopic dermatitis, after it failed to meet efficacy goals.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
